Immunomedics, Seattle Genetics in $2B cancer drug deal. ‘Seattle’ buys 2.8% stake

Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.

Read more